亞太藥業(002370.SZ)已累計收到拆遷補償款1.863億元
格隆匯 3 月 10日丨亞太藥業(002370.SZ)披露關於公司收到房屋拆遷補償款的進展,公司於2020年12月25日召開的第六屆董事會第二十六次會議審議通過了《關於簽署拆遷補償協議的議案》,同日,拆遷單位紹興市柯橋區中心城建設投資開發有限公司、受委託方紹興市柯橋區柯橋街道辦事處與公司簽署了《房屋拆遷貨幣補償協議》,紹興市柯橋區中心城建設投資開發有限公司以現金方式對公司柯橋廠區房屋拆遷進行補償,拆遷補償款總額為約2.66億元。
2021年3月10日,公司收到受委託方紹興市柯橋區柯橋街道辦事處轉付的第二筆拆遷補償款4000萬元。截至公吿披露日,公司已累計收到拆遷補償款1.863億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.